Gautam Patel Sells 17,410 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the sale, the director now directly owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Amneal Pharmaceuticals Stock Down 0.6 %

Shares of AMRX traded down $0.05 during trading hours on Monday, reaching $7.77. The stock had a trading volume of 1,020,280 shares, compared to its average volume of 935,632. The firm has a 50-day moving average of $8.28 and a 200 day moving average of $8.02. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.01 and a 52 week high of $9.48. The company has a market cap of $2.41 billion, a P/E ratio of -11.43 and a beta of 1.10.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP raised its holdings in Amneal Pharmaceuticals by 12.4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after acquiring an additional 1,179,830 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after purchasing an additional 710,598 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Amneal Pharmaceuticals by 114.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock valued at $10,026,000 after acquiring an additional 642,065 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after purchasing an additional 641,405 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on AMRX. Piper Sandler boosted their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Truist Financial lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Finally, StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.